Haleon stock

HLN · LSE · GBp

347.90 GBpChange from previous close: +0.90%Absolute change: +3.10 GBp

Close · November 16, 2026

Price history

−5.85% over the period

1 year: from 369.50 GBp (November 17, 2025) to 347.90 GBp (November 16, 2026), −5.85%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026347.90 GBp
October 30, 2026319.40 GBp
September 30, 2026337.60 GBp
August 28, 2026368.20 GBp
July 31, 2026363.30 GBp
June 30, 2026347.70 GBp
May 29, 2026336.70 GBp
April 30, 2026340.00 GBp
March 31, 2026373.80 GBp
February 27, 2026405.70 GBp
January 30, 2026378.90 GBp
December 31, 2025374.80 GBp
November 28, 2025370.90 GBp
November 17, 2025369.50 GBp

At a glance

  • The company

    Develops and sells consumer healthcare products including oral health, vitamins and supplements, respiratory, pain relief and digestive health products across multiple brands

  • Latest results

    Quarter to June 30, 2026 · EPS £0.04 (estimate £0.05)

TickerLandia's take on Haleon

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low310.50 GBp
52-wk high433.60 GBp

−19.76% from the 52-week high

Analysts · 18 analysts

Average target377.56 GBp+8.52% vs. price

Buy 9 · Hold 8 · Sell 1 · Buy

TickerLandia Fingerprint: Haleon

Compared with similar companies: low financial strength, high earnings stability, and low growth.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Haleon is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Haleon's P/E today is 18.8, below the median of its last 4 fiscal years (26.3; between 20.3 and 28.5 from 2022 to 2025). Haleon's P/E (trailing 12 months): 19.2, −23% against the median of a group of 11 similar companies (25.0).

P/E compared with its history

Compared with 11 similar companies

Haleon's metrics compared with similar companies
MetricHaleonPosition in the groupBand
P/E (trailing 12 months)19.2Middle
Forward P/E15.5Middle
Operating margin23.5%Middle
ROE10.1%Middle
Debt/equity0.50Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Haleon. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

£5.6B

Latest quarter · Q2 2026

Net income

£762M

Latest quarter · Q2 2026

Quarterly net margin

13.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
£30.27B
P/E
19.2
EPS
18.00 GBp
Volume
22.39M
Daily trading
€177.59M
Dividend yield
2.10%
Last ex-dividend on August 13, 2026

How Haleon is changing

All results
  • Revenue grew 2.2% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 150% of net income

Returns

Haleon returns with dividends

£1,000 invested in Haleon 3 years ago, on November 16, 2023, would be worth £1,122 today with dividends reinvested: +12.19% in total, +3.91% per year. On price alone it would be £1,060 (+6.03%).

PeriodHaleonFTSE 100£1,000 becomes
1 month−7.25%+0.53%£927
6 months+4.51%+6.94%£1,045
Year to date−7.18%+10.15%£928
1 year−3.94%+13.07%£961
3 years+12.19%+47.62%£1,122

Over the last 6 months it has done better than 22% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment

The chart in detail

Haleon: technical analysis

Haleon shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 16.2% below its all-time closing high (415.20 GBp, May 29, 2025).

Trend
No clear trend
RSI (14 sessions)
51
Between 30 and 70
vs 200-session average
−2.84%

Support and resistance

Price areas where Haleon has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance371.95 GBp+6.91%4 touches, last on August 26, 2026
  2. Resistance362.60 GBp+4.23%2 touches, last on April 29, 2026
  3. Resistance349.90 GBp+0.57%8 touches, last on September 24, 2026
  4. Last price347.90 GBp
  5. Support326.07 GBp−6.28%3 touches, last on October 2, 2026

Volatility and risk

Over the last year it has moved less than the FTSE 100.

Beta (1 year) vs FTSE 100
0.57
Volatility (60 sessions, annualised)
40.1%
Largest fall in the last year
−22.68%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Haleon and its competitors

Haleon develops, manufactures and sells consumer healthcare products across North America, Europe, the Middle East, Africa, Latin America and the Asia Pacific. Its oral health range includes toothpastes, mouthwashes and denture care under Sensodyne, Polident, Parodontax and Biotene, while Centrum and Caltrate cover vitamins, minerals and supplements. Its over-the-counter lines span cold, flu and allergy relief under Theraflu and Flonase, pain relief under Voltaren, Panadol and Advil, and digestive products under TUMS and ENO. A collaboration with Microsoft supports its digital, data and AI work.

Headquarters
Weybridge, United Kingdom
Employees
24,535
Founded
1715
Chief executive
Brian McNamara
Haleon and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
HaleonHLN$40.03B23.5%19.2+4.51%
Sandoz GroupSDZ$43.66B9.3%72.3+30.60%
Galderma GroupGALD$53.24B19.1%66.0+22.82%
MerckMRK$71.89B17.0%33.8+28.50%
Swedish Orphan BiovitrumSOBI$16.42B30.9%25.0+8.39%
IpsenIPN$15.16B27.4%26.9+0.60%

Same industry or related industries, similar size. Compare Haleon with its competitors · Full profile